SCIB

Scibase Holding

Market Cap 108.0M

SciBase är ett diagnostikbolag som grundades år 1998 av Stig Ollmar baserat på forskning som pågått sedan 1980-talet. Efter en grundlig forskning på Karolinska Institutet har SciBase har tagit fram Nevisense, ett icke invasivt, kompletterande diagnostikverktyg för att objektivt identifiera melanom. Nevisense är idag godkänt på den europeiska och australiensiska marknaden. Under sommaren 2017 fick Nevisense ett så kallat PMA– (pre market approval) godkännande, vilket gör att SciBase kan sälja Nevisense på den amerikanska marknaden. SciBase har 49 gällande patent i 6 patentfamiljer som skyddar produkten fram till 2023. Därutöver har bolaget 12 pågående ansökningar som är under behandling och som kan förlänga skyddet ytterligare.

+ more
0.00
Today
Day High
N/A
6.5
Day Low
N/A
Day Open
6.40
Prev Close
6.50
VWAP
N/A
Volume
0K
Turnover
0.000M
Top Broker
VWAP
6.4
Avg Volume
3K
Avg Turnover
0.018M
Top Brokers
PAS/NON
VWAP
6.5
Avg Volume
2K
Avg Turnover
0.015M
Top Brokers
PAS/NON
VWAP
6.6
Avg Volume
6K
Avg Turnover
0.037M
Top Brokers
ENS/UBS
52 week summary
Price Range
6.0
Last
20.8
Beta
N/A
Market Cap
108.0M
Total Return
-67.4%
Trailing P/E
-2.5
Div Yield
0.0%
Shares Outstanding
16.6M
Next Earnings Date
20 Aug
Stock Exchange
First North Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months -10.1%
Change 12 Months -67.4%
Volume Trend
Average Volume 10 vs 60 Days -70.4%
Price VS
52 Week High -68.7%
50 Day Moving Average 30.2%
200 Day moving Average 1.2%

Add article markers

Compare Scibase Holding to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
Last updated: 2017-03-27 Source: Redeye
Major Owners Equity Votes
SEB Venture Capital 12.7%
12.7%
SEB Pensionsstiftelse 12.6%
12.6%
Fouriertransform Aktiebolag 12.1%
12.1%
Strawberry Capital 6.2%
6.2%
Rothesay Ltd 5.4%
5.4%
Nordnet Pensionsförsäkring 4.1%
4.1%
Anders Walldov 4.1%
4.1%
L.P. Omega Fund Iv 1.3%
1.3%
Livsmedelsbörsen i Stockholm AB 2.8%
2.8%
Zentricity Holding AB 2.4%
2.4%
Last updated: 2018-05-01 Source: Redeye
Timeframe Transactions Net Shares
Last 12 weeks
1 Purchases
42,300
0 Sales
0
Last 24 weeks
1 Purchases
42,300
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Insider trades are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • -47.1%
  • -46.3%
  • -706.6%
  • -1,007.1%
  • -1,011.2%
  • -1,011.2%
  •  
  • -5.07
  • -5.07
  • 0.00
  •  
  • 8.3
  •  
  • 29.5
  • -3.9
  • -3.9
  • 39.3
  • 7.1
  • -0.7
  • -0.7
  • 1.1
  •  
  • 95.1%
  • 0.0%
  • -134
  • 12
  • 0.0
  • 2015
  •  
  •  
  • 134
  • 2
  • 5
  • 0
  • 142
  •  
  • 9
  • 0
  • 1
  • 0
  • 0
  • 0
  • 1
  • 12
  • 0
  • 153
  •  
  •  
  • 0
  • 8
  • 0
  • 8
  • 0
  • 0
  • 0
  • 8
  • 0
  • 0
  • 146
  • 0
  • 146
  • 153
  • 2015
  • 4
  • -46
  • 0
  • -42
  • 0
  • -42
  • 0
  • -42
  • -5
  • -1
  • -48
  • 2015 Q2
  • 1
  • -12
  • -11
  • 0
  • 0
  • 0
  • -11
  • 0
  • 0
  • 0
  • -11
  • 0
  • -11
  • 2015 Q3
  • 1
  • -11
  • -10
  • 0
  • 0
  • 0
  • -10
  • 0
  • 0
  • 0
  • -10
  • 0
  • -10
  • 2015 Q4
  • 1
  • -12
  • -11
  • 0
  • 0
  • 0
  • -11
  • 0
  • 0
  • 0
  • -11
  • 0
  • -11
  • 2016
  •  
  • -44.6%
  • -44.5%
  • -445.1%
  • -820.0%
  • -824.7%
  • -824.7%
  •  
  • -6.41
  • -6.41
  • 0.00
  •  
  • 8.3
  •  
  • 72.5
  • -3.0
  • -3.0
  • 24.5
  • 11.3
  • -1.4
  • -1.4
  • 1.7
  •  
  • 90.7%
  • 0.0%
  • -85
  • 8
  • 0.1
  • 2016
  •  
  •  
  • 85
  • 4
  • 4
  • 0
  • 93
  •  
  • 8
  • 0
  • 1
  • 0
  • 0
  • 0
  • 0
  • 9
  • 0
  • 102
  •  
  •  
  • 0
  • 9
  • 0
  • 9
  • 0
  • 0
  • 0
  • 9
  • 0
  • 0
  • 93
  • 0
  • 93
  • 102
  • 2016
  • 6
  • -59
  • 0
  • -53
  • 0
  • -53
  • 0
  • -53
  • 2
  • 2
  • -49
  • 2016 Q1
  • 1
  • -13
  • -12
  • 0
  • 0
  • 0
  • -12
  • 0
  • 0
  • 0
  • -12
  • 0
  • -12
  • 2016 Q2
  • 2
  • -16
  • -14
  • 0
  • 0
  • 0
  • -14
  • 0
  • 0
  • 0
  • -14
  • 0
  • -14
  • 2016 Q3
  • 2
  • -14
  • -12
  • 0
  • 0
  • 0
  • -12
  • 0
  • 0
  • 0
  • -12
  • 0
  • -12
  • 2016 Q4
  • 2
  • -16
  • -14
  • 0
  • 0
  • 0
  • -15
  • 0
  • 0
  • 0
  • -15
  • 0
  • -15
  • 2017
  •  
  • -39.3%
  • -38.2%
  • -551.7%
  • -608.6%
  • -619.1%
  • -619.1%
  •  
  • -2.56
  • -2.56
  • 0.00
  •  
  • 16.6
  •  
  • 23.0
  • -3.1
  • -3.1
  • 18.9
  • 3.4
  • -0.6
  • -0.5
  • 1.0
  •  
  • 98.1%
  • 1.8%
  • -107
  • 17
  • 0.1
  • 2017
  •  
  •  
  • 109
  • 3
  • 4
  • 0
  • 117
  •  
  • 8
  • 0
  • 1
  • 0
  • 0
  • 0
  • 0
  • 9
  • 0
  • 126
  •  
  •  
  • 0
  • 0
  • 0
  • 0
  • 2
  • 0
  • 0
  • 2
  • 0
  • 0
  • 124
  • 0
  • 124
  • 126
  • 2017
  • 7
  • -49
  • -1
  • -42
  • 0
  • -42
  • 1
  • -42
  • -9
  • -1
  • -52
  • 2017 Q1
  • 2
  • -13
  • -12
  • 0
  • 0
  • 0
  • -12
  • 0
  • 0
  • 0
  • -12
  • 0
  • -12
  • 2017 Q2
  • 2
  • -14
  • -12
  • 0
  • 0
  • 0
  • -12
  • 0
  • 0
  • 0
  • -12
  • 0
  • -12
  • 2017 Q3
  • 1
  • -10
  • -9
  • 0
  • 0
  • 0
  • -9
  • 0
  • 0
  • 0
  • -9
  • 0
  • -9
  • 2017 Q4
  • 2
  • -11
  • -10
  • -1
  • 0
  • 0
  • -10
  • 0
  • 0
  • 0
  • -10
  • 0
  • -10
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 Q1 E
  • 2018 Q2 E
  • 2018 Q3 E
  • 2018 Q4 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 Q1 E
  • 2019 Q2 E
  • 2019 Q3 E
  • 2019 Q4 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 Q1 E
  • 2020 Q2 E

Estimated Values are behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-05-01 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.